AAV Producer Cell Single-Locus Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing adeno-associated virus (AAV) vectors face challenges such as contamination from wild-type adenovirus, high costs, and labor-intensive processes, particularly in generating stable packaging and producer cell lines that meet quality requirements for gene therapy applications.
Innovation Solution
The development of nucleic acid vectors with a non-mammalian origin of replication, capable of holding at least 25 kilobases of DNA, which integrate all essential AAV genes into a single locus within the mammalian host cell genome, simplifying the production process and reducing costs by eliminating the need for multiple plasmids and transfection reagents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If stable packaging and producer cell lines are generated using conventional methods, then AAV vector production can be achieved, but the process becomes labor-intensive and expensive
Solution Approach 1:
The patent combines multiple AAV genes (rep, cap, and helper virus genes) into a single nucleic acid vector that integrates into the host cell genome at one locus. This merging of multiple genetic elements into one integrated construct eliminates the need for separate plasmids and reduces the complexity of generating stable cell lines, directly addressing the contradiction between production efficiency and process complexity.
2Reliability
If multiple plasmids are used for AAV gene delivery, then all essential AAV genes can be provided, but transfection reagents and costs increase
Solution Approach 1:
The invention merges all essential AAV genes (rep, cap, and helper virus genes) into a single nucleic acid vector. This single integrated vector can be delivered using a single transfection event, eliminating the need for multiple plasmids and multiple transfection reagents, thereby reducing costs while maintaining complete gene delivery.
Solution Approach 2:
The nucleic acid vector is designed to serve multiple functions simultaneously: it provides rep genes, cap genes, and helper virus genes all in one construct. This multi-functional vector eliminates the need for separate plasmids for each gene type, reducing the overall number of transfection reagents needed and lowering production costs.
3Productivity
If adenovirus is used as helper virus for AAV production, then AAV replication and virion production are enabled, but wild-type adenovirus contamination occurs
Solution Approach 1:
The patent extracts the helper virus genes from the wild-type adenovirus and places them into the nucleic acid vector under the control of inducible promoters. This allows the helper functions to be provided in a controlled manner without introducing wild-type adenovirus into the culture, eliminating contamination while maintaining AAV replication efficiency.
Solution Approach 2:
The invention uses inducible promoters to control the expression of helper virus genes, changing the expression parameters from constitutive to inducible. This allows helper functions to be activated only when needed for AAV production, preventing unwanted adenovirus replication and contamination while maintaining efficient AAV virion production.
4Reliability
If transient transfection method is used, then adenovirus-free AAV vectors are produced, but the process is labor-intensive and expensive
Solution Approach 1:
The patent combines all AAV genes and helper virus genes into a single nucleic acid vector that integrates into the host cell genome. This creates a stable cell line that can produce AAV vectors continuously without repeated transfections, maintaining adenovirus-free products while dramatically reducing labor intensity compared to transient transfection methods.
Data Source
AI summary
The invention relates to an adeno-associated virus (AAV) producer cell comprising nucleic acid sequences encoding: rep/cap gene; helper virus genes; and the DNA genome of the AAV vector particle, wherein the nucleic acid sequences are all integrated together at a single locus within the AAV producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that the nucleic acid vectors comprise nucleic acid sequences encoding: rep/cap gene, and helper virus genes. The invention also relates to uses and methods using the nucleic acid vectors in order to produce stable AAV packaging and producer cell lines.